EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSPKIG00000013540
Gene Symbol: GRIK2
4 Cross references
255 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSPKIG00000004789
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSPKIG00000005602
Gene Symbol: GRIK4
1 Cross references
250 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSPKIG00000017771
Gene Symbol: GRIK4
3 Cross references
188 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPKIG00000012638
Gene Symbol: GRIK5
3 Cross references
228 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPKIG00000017058
Gene Symbol: GRIK5
4 Cross references
162 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPKIG00000024710
Gene Symbol: GRM2
3 Cross references
274 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPKIG00000004812
Gene Symbol: GRM2
4 Cross references
274 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSPKIG00000014862
Gene Symbol: GRM3
3 Cross references
214 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPKIG00000001301
Gene Symbol: GRM4
3 Cross references
272 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPKIG00000003411
Gene Symbol: GRM4
3 Cross references
272 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSPKIG00000023293
Gene Symbol: GRM5
4 Cross references
149 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).